

## Disclosures

### Personal Commercial (4)

Company Name	Relationship Category	Compensation Level	Topic Area(s)
<i>Self</i>			
Abbott Laboratories	Research/Research Grants	Significant (>= \$5,000)	<i>Invasive CV Angio and Interventions</i>
Amgen Inc.	Consultant Fees/Honoraria	Modest (< \$5,000)	<i>Acute Coronary Syndromes</i>
Daiichi Sankyo	Speaker's Bureau	Modest (< \$5,000)	<i>Acute Coronary Syndromes</i>
terumo	Consultant Fees/Honoraria	Modest (< \$5,000)	<i>Invasive CV Angio and Interventions</i>

### Additional Personal Commercial Disclosures for Education Activities (0)

No disclosures on record

### Personal Organizational or Other Non-Commercial (11)

Non-Commercial Entity Name	Relationship Category	Compensation Level	Topic Area(s)
<i>Self</i>			
Abbott	Research/Research Grants ‡ unrestricted educational grant to my university to support a PhD studentship	Significant (>= \$5,000)	<i>Invasive CV Angio and Interventions</i>
AHA associate Editor Circulation CV Interventions	Other	Significant (>= \$5,000)	<i>Invasive CV Angio and Interventions</i>
BMS	Consultant Fees/Honoraria	Modest (< \$5,000)	<i>Prevention</i>
Daicchi Sankyo	Speaker's Bureau	Modest (< \$5,000)	<i>Acute Coronary Syndromes</i>
EAPCI	Other - Board Member	None (\$0)	<i>Invasive CV Angio and Interventions</i>
ESC	Other - esc nstemi 2020 guideline coordinator	None (\$0)	<i>Acute Coronary Syndromes</i>
NIHR	Other - interventional procedures panel	None (\$0)	<i>Other</i>
Pfizer	Consultant Fees/Honoraria	Modest (< \$5,000)	<i>Heart Failure and Cardiomyopathies</i>
TCTMD Senior clinicaql editor	Other	Significant (>= \$5,000)	<i>Other</i>
Terumo	Research/Research Grants ‡ unrestricted educational grant to my university, no personal funding	Significant (>= \$5,000)	<i>Acute Coronary Syndromes</i>
Terumo	Speaker's Bureau	Modest (< \$5,000)	<i>Invasive CV Angio and Interventions</i>

### Clinical Trial Enroller (0)

No disclosures on record

### Institutional Financial Decision-Making Role (0)

No disclosures on record

### Expert Witness Testimony (0)

No disclosures on record

‡ Commercial Funding Source | ‡ Trial Name

## Agreement

Certified Education Attestation | Signed on 10/2/2024

URL for full agreement: <http://disclosures.acc.org/Public/Definition/CertifiedEducationAttestationAgreement>

Confidentiality, Disclosure and Assignment Agreement | Signed on 10/2/2024

**Embargo** | Signed on 10/2/2024

URL for full agreement: <http://disclosures.acc.org/Public/Definition/EmbargoAgreement>

**On-Going Obligation Agreement** | Signed on 10/2/2024

---

## ACC and Disclosures

ACC is committed to ensuring balance, independence, objectivity, and scientific rigor in their governance, programmatic, educational, chapter, and other activities. Fulfilling this commitment depends on member and public confidence in the College's integrity and objectivity. The College recognizes that the activities of College members in their practice, research, and other volunteer and private endeavors could lead to the development of conflicts of interest. Therefore, the College has established a Disclosure Policy and conflict of interest management process as appropriate. All members involved in College governance, including all committees and task forces, programmatic, certified educational, chapter, and other activities must provide complete, timely, accurate, and signed disclosure statements. Compliance with this process is mandatory for participation in College activities.